JP2019515942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515942A5 JP2019515942A5 JP2019500021A JP2019500021A JP2019515942A5 JP 2019515942 A5 JP2019515942 A5 JP 2019515942A5 JP 2019500021 A JP2019500021 A JP 2019500021A JP 2019500021 A JP2019500021 A JP 2019500021A JP 2019515942 A5 JP2019515942 A5 JP 2019515942A5
- Authority
- JP
- Japan
- Prior art keywords
- ambrisentan
- treatment
- subject
- pharmaceutical composition
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 8
- 229960002414 ambrisentan Drugs 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 201000011200 hepatorenal syndrome Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| US62/310,221 | 2016-03-18 | ||
| EP16166046.9 | 2016-04-19 | ||
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| US201662437949P | 2016-12-22 | 2016-12-22 | |
| US62/437,949 | 2016-12-22 | ||
| PCT/EP2017/056476 WO2017158199A1 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515942A JP2019515942A (ja) | 2019-06-13 |
| JP2019515942A5 true JP2019515942A5 (enExample) | 2020-02-27 |
| JP7237362B2 JP7237362B2 (ja) | 2023-03-13 |
Family
ID=55808404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500021A Active JP7237362B2 (ja) | 2016-03-18 | 2017-03-20 | 急性腎不全の治療における使用のためのアンブリセンタン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (enExample) |
| EP (3) | EP3235496A1 (enExample) |
| JP (1) | JP7237362B2 (enExample) |
| KR (1) | KR20180121539A (enExample) |
| CN (1) | CN109069443A (enExample) |
| AU (1) | AU2017235618B2 (enExample) |
| BR (1) | BR112018067602A2 (enExample) |
| CA (1) | CA3015432A1 (enExample) |
| CL (1) | CL2018002638A1 (enExample) |
| DK (1) | DK3429566T3 (enExample) |
| ES (2) | ES2856960T3 (enExample) |
| HK (1) | HK1259616A1 (enExample) |
| IL (1) | IL261457B (enExample) |
| MX (1) | MX374534B (enExample) |
| SG (1) | SG11201808009SA (enExample) |
| WO (1) | WO2017158199A1 (enExample) |
| ZA (1) | ZA201805562B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| US20230165856A1 (en) * | 2020-04-29 | 2023-06-01 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| EP2183223A2 (en) * | 2007-07-31 | 2010-05-12 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| AU2013226944B2 (en) | 2012-02-29 | 2017-03-23 | Toray Industries, Inc. | Inhibitory agent for body cavity fluid accumulation |
| US20160015701A1 (en) * | 2013-03-08 | 2016-01-21 | Abbive Inc. | Methods of Treating Acute Kidney Injury |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509667A5 (enExample) | ||
| JP2021502066A5 (enExample) | ||
| JP2018184462A5 (enExample) | ||
| WO2018234568A3 (en) | HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION | |
| PH12018502742A1 (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
| JP2016515522A5 (enExample) | ||
| JP2016028092A5 (enExample) | ||
| JP2017537928A5 (enExample) | ||
| JP2016540026A5 (enExample) | ||
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| JP2020536085A5 (enExample) | ||
| JP2019515942A5 (enExample) | ||
| WO2015125152A3 (en) | Pharmaceutical compositions of asenapine | |
| JP2019527805A5 (enExample) | ||
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| JP2020531778A5 (enExample) | ||
| WO2017105881A8 (en) | Deuterated compounds for treating pain | |
| WO2017106798A3 (en) | Compositions and methods for treating gluten intolerance and disorders arising therefrom | |
| WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
| EP3296630A4 (en) | INFRARED HYDROGEN / OXYGEN BURNER | |
| JP2021508144A5 (enExample) | ||
| JP2017201524A5 (enExample) | ||
| JP2017516883A5 (enExample) | ||
| EA202090165A1 (ru) | Фармацевтическая композиция для предупреждения или лечения сердечно-сосудистых заболеваний, сопровождающихся диабетом, содержащая амлодипин, лозартан и розувастатин, и комбинированный препарат, содержащий ее | |
| JP2014240383A5 (enExample) |